Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
| Заболевание | Cirrhosis, Hepatocellular Carcinoma |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | National Cancer Institute (NCI) |
| Статус | Идёт, набор закрыт |
| Участники | 52 участн. |
| Вмешательство | Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Questionnaire Administration |
| Дата начала | 21.06.2017 |
| Дата завершения | 3.05.2023 |
| Публикация результатов | 15.04.2025 |
Кратко
This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Change in Serum AFP-L3%
| Group I (Simvastatin) | 0.24 ± 1.00 percent |
|---|---|
| Group II (Placebo) | -0.04 ± 0.11 percent |
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)